Specialities

Specialities

Bladder Cancer
Breast Cancer
Colorectal Cancer
COVID-19
Dermatologic Cancers
Diagnostics and Screening
Gastrointestinal Cancers
Genitourinary Cancer
Gynecologic Cancers
Hematology
Hematologic Malignancies
Head and Neck Cancer
Immunotherapy
Leukemia
Lymphoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Lung Cancer
Prostate Cancer
Renal Cancer
Endocrine Cancers
Pediatric Oncology
Policy
Sarcoma
Supportive Cancer Care
Soft Tissue Tumors
Neuro-oncology
Pathology
Radiology
Radiotherapy
Rare Diseases
Search

Trending Topic
3 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Foreword – touchREVIEWS in Oncology & Haematology, Volume 22, Issue 1, 2026

This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging targeted therapies and novel biological insights, the contributions highlight both recent progress and the significant […]

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin
touchEXPERT FOCUS

Innovations and advances in CML: Focus on navigating early-line options and maintaining quality of life

Topics Covered:
Hematology Hematologic Malignancies Leukemia
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Downloads Tab
Feedback
Slides
Practice Aid
Audio Version
Add Note

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

Which low-grade TKI side effect most impacts your patients’ quality of life?

Submit your answer to see the results and continue the video
Fatigue
   
Rash
   
Gastrointestinal
   
Musculoskeletal pain
   

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

Which area interests you the most for informing your future clinical practice?

Submit your answer to see the results and continue the video
Tyrosine kinase inhibitors with reduced dosing frequency
   
Combination strategies for treatment resistance
   
Novel approaches to achieve treatment-free remission
   
Patient-guided approaches to dose optimization
   

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

How confident are you in identifying the quality-of-life needs of your patients?

Submit your answer to see the results and continue the video
Not confident
   
Slightly confident
   
Moderately confident
   
Very confident
   
Open Nav Add Note

Expert Interviews

Dr Delphine Rea

Quality of life and the unmet needs of patients with CML in early-line settings
Duration: 11:04

Introduction

Start Time: 0:00

What is the current treatment landscape for CML, and how have therapeutic developments impacted life expectancy?

Start Time: 0:14

What are the key low-grade side effects associated with approved TKIs for treating CML?

Start Time: 2:45

How do TKIs differ in serious off-target side effects?

Start Time: 4:23

How do TKIs differ in treatment outcomes over the longer term?

Start Time: 7:16

What role can patient-reported outcome measures play in understanding patient needs?

Start Time: 9:12

Prof. Dr. Andreas Hochhaus

Recent clinical data on TKIs in CML and their impact on quality of life
Duration: 15:21

Introduction

Start Time: 0:00

How is the therapeutic landscape for CML evolving to address the unmet needs of patients with CML, including tolerability and treatment resistance?

Start Time: 0:16

What emerging treatments or combinations are under investigation to further improve outcomes in patients with CML?

Start Time: 5:16

What other strategies are being explored to further enhance quality of life for patients with CML, and what do the available data tell us?

Start Time: 8:02

Dr Ehab Atallah

Approaches for working with patients with CML to optimize their quality of life and treatment outcomes
Duration: 9:37

Introduction

Start Time: 0:00

Why is effective patient–physician communication important for addressing the unmet needs of patients with CML?

Start Time: 0:23

What strategies can clinicians use to improve patient QoL in the first line or following treatment resistance/intolerance?

Start Time: 2:21

How can clinicians work with patients to use SDM effectively to achieve better QoL outcomes?

Start Time: 7:36

What other tools are available to clinicians to support patients in participating in an effective SDM process?

Start Time: 8:26

Downloads

Download Slides

File Type: PDF File Size: 0.51 MB
Download

Download Practice Aid

File Type: PDF File Size: 0.76 MB
Download

Useful Tips

Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German and Spanish.
Associated slides for this activity are available under the Downloads tab.
A practice aid for this activity is available under the Downloads tab.

Got 2 minutes?

Your feedback is important to us.

1
Strongly Disagree
5
Strongly Agree
*
Mandatory Field

We’d love to hear your feedback on this activity. It helps us to continually improve our products.

The following educational objectives for this activity were met

Back to Activity
Next Step
Complete Step 1

Got 2 minutes?

Your feedback is important to us.

Back
Next Step
Complete Step 2

Got 2 minutes?

Your feedback is important to us.

Back
Next Step
Complete Step 3
Submit Feedback Submit Feedback
Complete Above Form

Please complete the below so we can prepare your certificate download.

touchEXPERT FOCUS

Innovations and advances in CML: Focus on navigating early-line options and maintaining quality of life

Back
Submit Accreditation Submit Accreditation
Complete Above Form
touchONCOLOGY

Check your Inbox

We've sent your certificate

Back to Activity
Close Popup
touchONCOLOGY

Thank you
for your Feedback!

Back to Activity
Close Popup

Video Navigation

Expert Interviews

Dr Delphine Rea

Quality of life and the unmet needs of patients with CML in early-line settings
Duration: 11:04

Introduction

Start Time: 0:00

What is the current treatment landscape for CML, and how have therapeutic developments impacted life expectancy?

Start Time: 0:14

What are the key low-grade side effects associated with approved TKIs for treating CML?

Start Time: 2:45

How do TKIs differ in serious off-target side effects?

Start Time: 4:23

How do TKIs differ in treatment outcomes over the longer term?

Start Time: 7:16

What role can patient-reported outcome measures play in understanding patient needs?

Start Time: 9:12

Prof. Dr. Andreas Hochhaus

Recent clinical data on TKIs in CML and their impact on quality of life
Duration: 15:21

Introduction

Start Time: 0:00

How is the therapeutic landscape for CML evolving to address the unmet needs of patients with CML, including tolerability and treatment resistance?

Start Time: 0:16

What emerging treatments or combinations are under investigation to further improve outcomes in patients with CML?

Start Time: 5:16

What other strategies are being explored to further enhance quality of life for patients with CML, and what do the available data tell us?

Start Time: 8:02

Dr Ehab Atallah

Approaches for working with patients with CML to optimize their quality of life and treatment outcomes
Duration: 9:37

Introduction

Start Time: 0:00

Why is effective patient–physician communication important for addressing the unmet needs of patients with CML?

Start Time: 0:23

What strategies can clinicians use to improve patient QoL in the first line or following treatment resistance/intolerance?

Start Time: 2:21

How can clinicians work with patients to use SDM effectively to achieve better QoL outcomes?

Start Time: 7:36

What other tools are available to clinicians to support patients in participating in an effective SDM process?

Start Time: 8:26

Listen on the Go

Listen on Amazon Music
Listen on Apple Podcasts
Listen on Spotify
Close Popup

Learning Objectives & Overview

Faculty & Disclosures

Downloads

Overview
Faculty
Downloads
Feedback

Learning Objectives

After watching this activity, participants should be better able to:

  • Recall unmet needs in chronic myeloid leukaemia (CML) care, including quality of life considerations for patients across first-line and resistance/intolerance settings
  • Appraise the latest clinical data for approved and emerging therapies for CML across first-line and resistance/intolerance settings to optimize quality of life
  • Summarize approaches to optimizing patient quality of life and treatment outcomes in CML, including patient–physician communication strategies

Overview

In these interviews, three renowned CML experts discuss the unmet needs in CML care, focusing on quality of life across first-line and resistance or intolerance settings. They explore the latest clinical data on approved and emerging therapies as well as strategies to optimize effective patient–physician communication.

Target Audience

This activity has been designed to meet the educational needs of haematologists, haematologist-oncologists and oncologists.

 

Faculty & Disclosures3

Dr Delphine Rea

Hôpital Saint-Louis, Paris, France
More Information
Close Popup

Dr Delphine Rea

Hôpital Saint-Louis, Paris, France

Biography

Dr Delphine Rea is appointed at Hôpital Saint-Louis, Paris, France, where she works as a physician in the Department of Hematology. Her main clinical and research interest focuses on malignant myeloid disorders.

read more

Dr Rea is responsible for the CML clinical care and research programme, and she has been the principal investigator or investigator on many academic and industry-sponsored clinical trials dedicated to CML, including pivotal studies that have led to the approval of tyrosine kinase inhibitors or treatment-free remission studies.

Dr Rea is on the board of directors of the French cooperative group of CML (Fi-LMC). She also contributes to the CML project of the European LeukemiaNet, the organization committee of the European School of Haematology (ESH) iCMLf annual conference, the Society of Hematologic Oncology (SOHO) annual meeting education committee and the scientific advisory board of iCMLf.

Dr Delphine Rea discloses: Advisory board or panel fees from Ascentage Pharma, Enliven Therapeutics, Incyte, Novartis and Terns Pharmaceuticals Inc. Consultancy fees from Novartis and Terns Pharmaceuticals Inc.

Dr Ehab Atallah

Prof. Dr. Andreas Hochhaus

Prof. Dr. Andreas Hochhaus

Jena University Hospital, Jena, Germany
More Information
Close Popup

Prof. Dr. Andreas Hochhaus

Jena University Hospital, Jena, Germany

Biography

Prof. Dr. Andreas Hochhaus is head of the Department of Hematology and Medical Oncology and speaker of the Central German Comprehensive Cancer Center at the Jena University Hospital, Jena, Germany. He was awarded the Endowed Professorship for Leukaemia Research from the German José Carreras Leukaemia Foundation in 2007.

read more

Prof. Dr. Hochhaus is interested in treatment optimization for CML and has been involved in the management of randomized CML studies of the German CML Study Group for more than 35 years.

As chair of the German CML Alliance, his focus is to enhance access to clinical trials for all patients. Prof. Dr. Hochhaus’ special interests are new drugs, molecular monitoring of residual disease and mechanisms of resistance in CML. He received the iCMLf Goldman Prize in 2022 and the CML Patients Advocacy Award in 2025.

Prof. Dr. Hochhaus is the current president of the German Society of Hematology and Medical Oncology, and a member of the European Hematology Association (EHA) and the American Society of Hematology (ASH). He served as president of the annual meeting of the German, Austrian and Swiss societies of haematology and oncology in 2016 and the German Cancer Congress in 2020. Prof. Dr. Hochhaus has published over 720 peer-reviewed papers and is regularly invited to speak at national and international symposia.

Prof. Dr. Andreas Hochhaus discloses: Advisory board or panel fees from Novartis. Grants/research support fees from Bristol Myers Squibb, Enliven Therapeutics, Incyte, Novartis, Pfizer, Takeda and Terns Pharmaceuticals Inc.

Dr Delphine Rea

Dr Ehab Atallah

Dr Ehab Atallah

Medical College of Wisconsin, Milwaukee, WI, USA
More Information
Close Popup

Dr Ehab Atallah

Medical College of Wisconsin, Milwaukee, WI, USA

Biography

Dr Ehab Atallah is a professor of medicine and associate director of the cancer service line in the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in leukaemia, myelodysplastic syndromes, myeloproliferative neoplasms and other bone marrow failure disorders at Froedtert Hospital.

read more

Dr Atallah is board certified/eligible in internal medicine, medical oncology and haematology. He has authored numerous publications, including journal articles, meeting abstracts and book chapters. His current research interests are treatment of patients with CML, chronic lymphocytic leukaemia, acute lymphocytic leukaemia, acute myelogenous leukaemia, myeloproliferative neoplasms and myelodysplastic syndromes.

Dr Atallah currently serves as the co-chair of the Eastern Cooperative Group (ECOG) leukaemia committee. He is the administrative director of the H Jean Khoury Cure CML Consortium (HJKC3). The HJKC3 was established in 2016 and is a collaborative effort of physicians and researchers at 21 academic medical centres committed to CML research and improving patient care and quality of life.

Dr Ehab Atallah discloses: Advisory board or panel fees from AstraZeneca, Handa, Novartis, Syndax Pharmaceuticals and Rigel (relationship terminated). Consultancy fees from Actinium, Geron and Handa. Grants/research support from Novartis. Other financial or material support (royalties, patent, etc.) fees from Uptodate. Speaker’s bureau fees from AbbVie, Syndax Pharmaceuticals and Bristol Myers Squibb (relationship terminated).

Prof. Dr. Andreas Hochhaus

Dr Delphine Rea

Downloads
2

View and download resources from this activity to support your learning and share with colleagues

English Downloads

Download Slides

File Type: PDF
File Size: 0.51 MB
Download

Download Practice Aid

File Type: PDF
File Size: 0.76 MB
Download

You Might Also Like9

Navigation Podcast Add Note

Video Navigation

Expert Interviews

Dr Delphine Rea

Quality of life and the unmet needs of patients with CML in early-line settings
Duration: 11:04

Introduction

Start Time: 0:00

What is the current treatment landscape for CML, and how have therapeutic developments impacted life expectancy?

Start Time: 0:14

What are the key low-grade side effects associated with approved TKIs for treating CML?

Start Time: 2:45

How do TKIs differ in serious off-target side effects?

Start Time: 4:23

How do TKIs differ in treatment outcomes over the longer term?

Start Time: 7:16

What role can patient-reported outcome measures play in understanding patient needs?

Start Time: 9:12

Prof. Dr. Andreas Hochhaus

Recent clinical data on TKIs in CML and their impact on quality of life
Duration: 15:21

Introduction

Start Time: 0:00

How is the therapeutic landscape for CML evolving to address the unmet needs of patients with CML, including tolerability and treatment resistance?

Start Time: 0:16

What emerging treatments or combinations are under investigation to further improve outcomes in patients with CML?

Start Time: 5:16

What other strategies are being explored to further enhance quality of life for patients with CML, and what do the available data tell us?

Start Time: 8:02

Dr Ehab Atallah

Approaches for working with patients with CML to optimize their quality of life and treatment outcomes
Duration: 9:37

Introduction

Start Time: 0:00

Why is effective patient–physician communication important for addressing the unmet needs of patients with CML?

Start Time: 0:23

What strategies can clinicians use to improve patient QoL in the first line or following treatment resistance/intolerance?

Start Time: 2:21

How can clinicians work with patients to use SDM effectively to achieve better QoL outcomes?

Start Time: 7:36

What other tools are available to clinicians to support patients in participating in an effective SDM process?

Start Time: 8:26

Add a Note

Note Time: 00:00
Save Note
touchONCOLOGY
touchEXPERT FOCUS

This activity is for healthcare professionals outside of the USA and UK.

This independent medical education is supported by Novartis and is provided by touchIME.

Continue
Decline
Close Popup
touchONCOLOGY
touchEXPERT FOCUS

Innovations and advances in CML: Focus on navigating early-line options and maintaining quality of life

This activity is for healthcare professionals outside of the USA and UK.

Back to Homepage
Close Popup
touchONCOLOGY

Could not verify Country/IP Address.

We were unable to verify your IP address, please try again later. If you are using a method to hide your IP address, such as a VPN or proxy, please disable this and try again.

Return to Homepage
touchONCOLOGY touchONCOLOGY

Register now for FREE access to

  • 1000+ topical and insightful peer-reviewed journal articles
  • 100+ hours of bite-sized congress highlights
  • 10 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • Concise email updates and newsletters so you never miss out

This activity is for:

Healthcare professionals outside of the USA and UK.

This independent medical education is supported by Novartis and is provided by touchIME.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

This content is intended only for healthcare professionals outside the USA and UK.

Launch date: 26 November 2025.

Latest articles videos and clinical updates - straight to your inbox

Close Popup